ReviewJournal of fungi (Basel, Switzerland)2018
Challenges and Opportunities in the Management of Onychomycosis.
Review in Journal of fungi (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04084782 (An Internet Mediated Research Study to Assess the Quality of Life of Consumers With Self-reported Fungal Nail Infection), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Internet Mediated Research Study to Assess the Quality of Life of Consumers With Self-reported Fungal Nail Infection (Onychomycosis) During Treatment With Scholl Fungal Nail.
Who cites it
27 citing papers in PubMed, 66 citations in OpenAlex.
- Combination of Q-switched 1,064 and 532 nm Nd: YAG laser in the treatment of toenail onychomycosis: a pilot study.Lasers in medical science · 2025Trial
- Trial
- Penetration and Preliminary Efficacy of a Novel Nitric Oxide-Releasing Gel for Onychomycosis.Journal of fungi (Basel, Switzerland) · 2025Article
- Efficacy and Safety of Voriconazole for Difficult-to-Treat Distal Lateral Subungual Onychomycosis (DLSO).Pathogens (Basel, Switzerland) · 2025Article
- Enhanced Efinaconazole Permeation and Activity AgainstPharmaceutics · 2025Article
- Onychomycosis among cancer patients undergoing chemotherapy in Tehran, Iran: a cross-sectional study.Iranian journal of microbiology · 2025Article
- Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment.RSC advances · 2025Review
- Article
- Prevalence and Risk Factors Predicting Onychomycosis in Patients with and Without Diabetes Mellitus in Spain: A Cross-Sectional Study.Journal of fungi (Basel, Switzerland) · 2024Article
- Retrospective Analysis of Onychomycosis Risk Factors Using the 2003-2014 National Inpatient Sample.Dermatology practical & conceptual · 2024Article
- Treatment Options for Onychomycosis: Efficacy, Side Effects, Adherence, Financial Considerations, and Ethics.The Journal of clinical and aesthetic dermatology · 2024Review
- New Formulation-Microporation Combination Approaches to Delivering Ciclopirox across Human Nails.Pharmaceutics · 2024Article
- Toenail Onychomycosis with or without Diabetes in Canada: Patient Treatment Preferences and Health State Utilities.Patient preference and adherence · 2024Article
- A Review of Antifungal Susceptibility Testing for Dermatophyte Fungi and It's Correlation with Previous Exposure and Clinical Responses.Journal of fungi (Basel, Switzerland) · 2022Review
- Onychomycosis: Recommendations for Diagnosis, Assessment of Treatment Efficacy, and Specialist Referral. The CONSONANCE Consensus Project.Dermatology and therapy · 2022Article
- In Silico Drug Screening Based Development of Novel Formulations for Onychomycosis Management.Gels (Basel, Switzerland) · 2021Article
- Apiaceae Essential Oils: Boosters of Terbinafine Activity against Dermatophytes and Potent Anti-Inflammatory Effectors.Plants (Basel, Switzerland) · 2021Article
- Molecular characterization and antifungal activity against non-dermatophyte molds causing onychomycosis.Scientific reports · 2021Article
- Constant Voltage Iontophoresis Technique to Deliver Terbinafine via Transungual Delivery System: Formulation Optimization Using Box-Behnken Design and In Vitro Evaluation.Pharmaceutics · 2021Article
- Application of central composite design for the optimization of itraconazole loaded nail lacquer formulation.3 Biotech · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Onychomycosis is an increasingly common fungal nail infection, chiefly caused by dermatophyte fungi. The disease is notoriously difficult to treat due to the deep-seated nature of fungi within the nail plate, prolonged treatment requirements, poor patient adherence and frequent recurrences. Given the poor efficacy of currently available topical and systemic therapies, there is a renewed interest in exploring alternative treatment modalities for onychomycosis. Natural therapies, physical treatments and various combination therapies have all shown potential for the management of onychomycosis, though research on many of these methods is still in preliminary stages. Further large, well-designed, randomised controlled trials are necessary to confirm the efficacy of these novel treatments in order to make formal recommendations regarding their use in the management of onychomycosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.